Key Folic Acid References*

1. Agamanolis DP, Chester EM, Victor M, Kark JA, Hines JD, Harris JW. Neuropathology of experimental vitamin B12 deficiency in monkeys. *Neurology.* 1976;26(10):905-914.
2. American Academy of Pediatrics. Folic acid for the prevention of neural tube defects. American Academy of Pediatrics. Committee on Genetics. *Pediatrics.* 1999;104(2 Pt 1):325-327.
3. Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. *Mutation Research.* 2001;475:7-20.
4. Bentley JR, Ferrini RL, Hill LL. American College of Preventive Medicine public policy statement. Folic acid fortification of grain products in the U.S. to prevent neural tube defects. *American Journal of Preventive Medicine.* 1999;16(3):264-267.
5. Beresford SA. How do we get enough folic acid to prevent some neural tube defects? [letter; comment]. *American Journal of Public Health.* 1994;84(3):348-350.
6. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention [corrected; erratum to be published]. *New England Journal of Medicine.* 1999;341(20):1485-1490.
7. Blackman BT. What vitamins should I be taking? *New England Journal of Medicine.* 1914;346(24):1914-1916.
8. Blount BC, Mack MM, Wehr CM, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. *Proceedings of the National Academy of Sciences of the United States of America.* 1997;94(7):3290-3295.
9. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. *Annals of Internal Medicine.* 1999;131(5):352-355.
10. Bostom AG, Selhub J, Jacques PF, Rosenberg IH. Power Shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour. *Annals of Internal Medicine.* 2001;135(2):133-137.
11. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. *Archives of Internal Medicine.* 1999;159(10):1077-1080.
12. Botto LD, Moore CA, Khoury MJ, Erickson JD. Neural-tube defects. *New England Journal of Medicine.* 1999;341(20):1509-1519.
13. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *JAMA.* 1995;274(13):1049-1057.

---

* * This listing of key references was last updated on 09/29/03 and covers topics related to folic acid and its relationship to birth defects, stroke, cardiovascular disease and neurological disorders. For further information contact Dr. Godfrey Oakley, M.D.

14. Bower C. Fortification of food with folic acid and the prevention of neural tube defects.[comment]. *New Zealand Medical Journal.* 2003;116(1168):U292.
15. Brent RL, Oakley GP, Jr., Mattison DR. The unnecessary epidemic of folic acid-preventable spina bifida and anencephaly. *Pediatrics.* 2000;106(4):825-827.
16. Brouwer DA, Welten HT, Reijngoud DJ, van Doormaal JJ, Muskiet FA. Plasma folic acid cutoff value, derived from its relationship with homocyst(e)ine. *Clinical Chemistry.* 1998;44(7):1545-1550.
17. Brown JE, Jacobs DR, Jr., Hartman TJ, et al. Predictors of red cell folate level in women attempting pregnancy. *JAMA.* 1997;277(7):548-552.
18. Campbell MK, Demark-Wahnefried W, Symons M, et al. Fruit and vegetable consumption and prevention of cancer: the Black Churches United for Better Health project. *American Journal of Public Health.* 1999;89(9):1390-1396.
19. Canfield MA, Anderson JL, Waller DK, Palmer SE, Kaye CI. Folic acid awareness and use among women with a history of a neural tube defect pregnancy--Texas, 2000-2001. *Morbidity & Mortality Weekly Report. Recommendations & Reports.* 2002;51(RR-13):16-19.
20. Centers for Disease Control and Prevention. Use of folic acid for prevention of spina bifida and other neural tube defects--1983-1991. *MMWR - Morbidity & Mortality Weekly Report.* 1991;40(30):513-516.
21. Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. *MMWR - Morbidity & Mortality Weekly Report.* 1992;41(RR-14):1-7.
22. Centers for Disease Control and Prevention. Folate status in women of childbearing age--United States, 1999. *MMWR - Morbidity & Mortality Weekly Report.* 2000;49(42):962-965.
23. Choumenkovitch SF, Jacques PF, Nadeau MR, Wilson PW, Rosenberg IH, Selhub J. Folic acid fortification increases red blood cell folate concentrations in the Framingham study. *Journal of Nutrition.* 2001;131(12):3277-3280.
24. Choumenkovitch SF, Selhub J, Wilson PW, Rader JI, Rosenberg IH, Jacques PF. Folic acid intake from fortification in United States exceeds predictions. *Journal of Nutrition.* 2002;132(9):2792-2798.
25. Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. *Seminars in Thrombosis & Hemostasis.* 2000;26(3):341-348.
26. Committee on Medical Aspects of Food and Nutrition Policy (COMA) of the Department of Health (UK). *Folic acid and the prevention of disease. Report of the committee on medical aspects of food and nutrition policy.* London: The Stationery Office; 2000. 0-11-322304-8.
27. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *New England Journal of Medicine.* 1992;327(26):1832-1835.
28. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects. Implications for prevention. *JAMA.* 1995;274(21):1698-1702.
29. de Bree A, Verschuren WM, Blom HJ, Kromhout D. Association between B vitamin intake and plasma homocysteine concentration in the general Dutch

population aged 20-65 y. *American Journal of Clinical Nutrition.* 2001;73(6):1027-1033.
30. De Walle HE, De Jong-Van Den Berg LT. Insufficient folic acid intake in the Netherlands: What about the future? *Teratology.* 2002;66(1):40-43.
31. de Walle HEK, de Jong-van den Berg LTW, Cornel MC. Periconceptional folic acid intake in the northern Netherlands. *Lancet.* 1999;353(3 August):1187.
32. de Walle HEK, van der Pal KM, de Jong-van den Berg LTW, et al. Effect of mass media campaign to reduce socioeconomic differences in women's awareness and behavior concerning use of folic acid: cross sectional study. *Br. Med. J.* 1999;319(31 July):291-292.
33. Delpre G, Stark P, Niv Y. Sublingual therapy for cobalamin deficiency as an alternative to oral and parenteral cobalamin supplementation. *Lancet.* 1999;354(9180):740-741.
34. Dickinson CJ. Does folic acid harm people with vitamin B12 deficiency? *QJM.* 1995;88(5):357-364.
35. Erickson D, Mulinare J, Yang Q, et al. Folate status in women of childbearing age, by race/ethnicity--United States, 1999-2000. *MMWR - Morbidity & Mortality Weekly Report.* 2002;51(36):808-810.
36. Erickson JD. Folic acid and prevention of spina bifida and anencephaly. 10 years after the U.S. Public Health Service recommendation. *Morbidity & Mortality Weekly Report. Recommendations & Reports.* 2002;51(RR-13):1-3.
37. Ericson A, Kallen B, Aberg A. Use of multivitamins and folic acid in early pregnancy and multiple births in Sweden. *Twin Research.* 2001;4(2):63-66.
38. Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in adults: scientific review. *JAMA.* 2002;287(23):3116-3126.
39. Feldkamp M, Friedrichs M, Carey JC. Decreasing prevalence of neural tube defects in Utah, 1985-2000. *Teratology.* 2002;66(1).
40. Fenech M. The role of folic acid and Vitamin B12 in genomic stability of human cells. *Mutation Research.* 2001;475(1-2):57-67.
41. Fletcher RH, Fairfield KM. Vitamins for chronic disease prevention in adults: clinical applications. *JAMA.* 2002;287(23):3127-3129.
42. Flood VM, Webb KL, Smith W, et al. Folate fortification: potential impact on folate intake in an older population. *European Journal of Clinical Nutrition.* 2001;55(9):793-800.
43. Food and Drug Administration. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. *Fed Regist.* 1996;61:8781-8807.
44. Food and Drug Administration. Food standards: health claims and label statements; folate and neural tube defects. *Fed Regist.* March 5, 1996 1996;61(44):8752-8781.
45. Food and Drug Administration. Food standards. *Fed Regist.* 1996;61:8781-8797.
46. Food and Nutrition Board IoM. Dietary reference intakes for thiamin, riboflavin, niacin, folate, vitamin B12, pantothenic acid, biotin, and choline/ a report of the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins and Choline and subcommittee on Upper Reference Levels of Nutrients. 1998.

47. Freire WB, Hertrampf E, Cortes F. Effect of folic acid fortification in Chile: preliminary results. *European Journal of Pediatric Surgery.* 2000;10(Suppl 1):42-43.
48. Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. *Annals of Internal Medicine.* 1998;129(7):517-524.
49. Graham I. Homocysteine in health and disease. *Annals of Internal Medicine.* 1999;131(5):387-388.
50. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. *JAMA.* 1997;277(22):1775-1781.
51. Green T, Newton R, Bourn D. Estimated folic acid intakes from simulated fortification of the New Zealand food supply.[comment]. *New Zealand Medical Journal.* 2003;116(1168):U294.
52. Gucciardi E, Pietrusiak MA, Reynolds DL, Rouleau J. Incidence of neural tube defects in Ontario, 1986-1999. *CMAJ: Canadian Medical Association Journal.* 2002;167(3):237-240.
53. Gunter EW, Bowman BA, Caudill SP, Twite DB, Adams MJ, Sampson EJ. Results of an international round robin for serum and whole-blood folate. *Clinical Chemistry.* 1996;42(10):1689-1694.
54. Hathcock JN, Troendle GJ. Oral cobalamin for treatment of pernicious anemia? [letter; comment]. *JAMA.* 1991;265(1):96-97.
55. Herbert V, Bigaouette J. Call for endorsement of a petition to the Food and Drug Administration to always add vitamin B-12 to any folate fortification or supplement. *American Journal of Clinical Nutrition.* 1997;65(2):572-573.
56. Hill BA. The environment and disease: Association or causation? *Proc Royal Soc Medicine.* 1965;58:295-300.
57. Homocysteine Studies C. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.[comment]. *Jama.* 2002;288(16):2015-2022.
58. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. *JAMA.* 2001;285(23):2981-2986.
59. Hook EB. Folic acid: abortifacient or pseudoabortifacient? [letter; comment.] [see comments.]. *American Journal of Medical Genetics.* 2000;92(5):301-302.
60. Huber A, Wallins L, DeRusso P. Folate nutriture in pregnancy. *J Am Diet Assoc.* 1988;88:791-795.
61. Indian Council of Medical Research (ICMR) Collaborating Centres and Central Technical Co-ordinating Unit I, New Delhi. Multicentric study of efficacy of periconceptional folic acid containing vitamin supplementation in prevention of open neural tube defects from India. *Indian J Med Res.* 2000;112(December 2000):206-211.
62. Institute of Medicine. Dietary Reference Intake: Folate, other B vitamins and choline. *Institute of Medicine: Washington D.C.: National Academy Press.* 1998.
63. Itikala PR, Ruuska SE, Oakley GP, Jr., Kloeblen-Tarver AS, Klein L. Periconceptional intake of folic acid among low-income women. *JAMA.* 2000;283(23):3074.

64. Jacob RA, Wu MM, Henning SM, Swendseid ME. Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. *Journal of Nutrition.* 1994;124(7):1072-1080.
65. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. *American Journal of Clinical Nutrition.* 2001;73(3):613-621.
66. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *New England Journal of Medicine.* 1999;340(19):1449-1454.
67. Johnston RB, Jr. Folic acid: new dimensions of an old friendship. *Advances in Pediatrics.* 1997;44:231-261.
68. Kang SS, Wong PW, Bock HG, Horwitz A, Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. *American Journal of Human Genetics.* 1991;48(3):546-551.
69. Kang SS, Wong PW, Norusis M. Homocysteinemia due to folate deficiency. *Metabolism: Clinical & Experimental.* 1987;36(5):458-462.
70. Kark JD, Selhub J, Adler B, et al. Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. *Annals of Internal Medicine.* 1999;131(5):321-330.
71. Kittner SJ, Giles WH, Macko RF, et al. Homocyst(e)ine and risk of cerebral infarction in a biracial population : the stroke prevention in young women study. *Stroke.* 1999;30(8):1554-1560.
72. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis.[comment]. *Jama.* 2002;288(16):2023-2031.
73. Kluijtmans LA, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. *Blood.* 2003;101(7):2483-2488.
74. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. *British Medical Journal Clinical Research Ed.* 1981;282(6275):1509-1511.
75. Lawrence JM, Petitti DB, Watkins M, Umekubo MA. Trends in serum folate after food fortification. *Lancet.* 1999;354(9182):915-916.
76. Lewis CA, Pancharuniti N, Sauberlich HE. Plasma folate adequacy as determined by homocysteine level. *Annals of the New York Academy of Sciences.* 1992;669:360-362.
77. Lewis CJ, Crane NT, Wilson DB, Yetley EA. Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use. *American Journal of Clinical Nutrition.* 1999;70(2):198-207.
78. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. *New England Journal of Medicine.* 1988;318:1720-1728.

79. Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. *American Journal of Clinical Nutrition.* 1994;60(1):2-11.
80. Lumley J, Watson L, Watson M, Bower C. Modelling the potential impact of population-wide periconceptional folate/multivitamin supplementation on multiple births. *BJOG.* 2001;108(9):937-942.
81. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. *Cancer Research.* 1997;57(6):1098-1102.
82. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. *New England Journal of Medicine.* 1998;338(15):1009-1015.
83. Malinow MR, Nieto FJ, Kruger WD, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. *Arteriosclerosis, Thrombosis & Vascular Biology.* 1997;17(6):1157-1162.
84. Mark SD, Wang W, Fraumeni JF, et al. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. *American Journal of Epidemiology.* 1996;143(7):658-664.
85. Martin J, Smith B, Mathews T, Ventura M. Births and deaths: preliminary data for 1998. *National Vital Statistics Reports.* 1999;47(Table E).
86. Mason JB, Levesque T. Folate: effects on carcinogenesis and the potential for cancer chemoprevention. *Oncology (Huntington).* 1996;10(11):1727-1736, 1742-1723; discussion 1743-1724.
87. Mathews TJ, Honein MA, Erickson JD. Spina bifida and anencephaly prevalence--United States, 1991-2001. *Morbidity & Mortality Weekly Report. Recommendations & Reports.* 2002;51(RR-13):9-11.
88. McDonnell R, Johnson Z, Doyle A, Sayers G. Determinants of folic acid knowledge and use among antenatal women. *Journal of Public Health Medicine.* 1999;21(2):145-149.
89. Meyer RE, Siega-Riz AM. Sociodemographic patterns in spina bifida birth prevalence trends--North Carolina, 1995-1999. *Morbidity & Mortality Weekly Report. Recommendations & Reports.* 2002;51(RR-13):12-15.
90. Ministry of Health. *Improving folate intake in New Zealand: policy implications.* Wellington: Ministry of Health; August 2003 2003.
91. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. *Lancet.* 1991;338(8760):131-137.
92. Muhammad R, Fernhoff P, Rasmussen S, et al. Neurologic impairment in children associated with maternal dietary deficiency of cobalamin--Georgia, 2001. *MMWR - Morbidity & Mortality Weekly Report.* 2003;52(4):61-64.
93. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. *New England Journal of Medicine.* 1997;337(4):230-236.

94. Nygard O, Vollset SE, Refsum H, Brattstrom L, Ueland PM. Total homocysteine and cardiovascular disease. *Journal of Internal Medicine.* 1999;246(5):425-454.
95. Oakley G. Global prevention of all folic acid-preventable spina bifida and anencephaly by 2010. *Community Genetics.* 2002;5:70-77.
96. Oakley G, Wald N, Omenn G. Provide the citizens of New Zealand the miracle of folic acid fortification.[comment]. *New Zealand Medical Journal.* 2003;116(1168):U302.
97. Oakley GP, Jr. Folic acid-preventable spina bifida and anencephaly. *JAMA.* 1993;269(10):1292-1293.
98. Oakley GP. Taking a folic acid supplement probably would reduce cardiovascular disease rates in the United States. *J Coronary Art Dis Index and Review.* 1996;II:10-12.
99. Oakley GP, Jr. Let's increase folic acid fortification and include vitamin B-12. *American Journal of Clinical Nutrition.* 1997;65(6):1889-1890.
100. Oakley GP, Jr. Eat right and take a multivitamin. *New England Journal of Medicine.* 1998;338(15):1060-1061.
101. Oakley GP, Jr. Prevention of neural-tube defects. *New England Journal of Medicine.* 1999;341(20):1546.
102. Oakley GP. Delaying folic acid fortification of flour. *BMJ.* 2002;324(7350):1348-1349.
103. Oakley GP, Jr. Inertia on folic acid fortification: public health malpractice. *Teratology.* 2002;66(1):44-54.
104. Oakley GP, Jr. Folic acid fortification: time for a concentrated effort. *CMAJ: Canadian Medical Association Journal.* 2002;167(8):848-849.
105. Oakley GP, Jr., Adams MJ, Dickinson CM. More folic acid for everyone, now. *Journal of Nutrition.* 1996;126(3):751S-755S.
106. Oakley GP, Jr., Erickson JD, Adams MJ, Jr. Urgent need to increase folic acid consumption. *JAMA.* 1995;274(21):1717-1718.
107. Oakley GP, Erickson JD, James LM, Mulinare J, Cordero JF. Prevention of Folic Acid-Preventable Spina Bifida and Anencephaly. Paper presented at: Ciba Foundation Symposium, 1993.
108. O'Connor DL. Four years after enhanced folic acid fortification of the Canadian food supply--how are we doing? [letter; comment.]. *Canadian Journal of Public Health. Revue Canadienne de Sante Publique.* 2002;93(4):245-248.
109. O'Keefe CA, Bailey LB, Thomas EA, et al. Controlled dietary folate affects folate status in nonpregnant women. *Journal of Nutrition.* 1995;125(10):2717-2725.
110. Persad VL, Van den Hof MC, Dube JM, Zimmer P. Incidence of open neural tube defects in Nova Scotia after folic acid fortification. *CMAJ: Canadian Medical Association Journal.* 2002;167(3):241-245.
111. Pfeiffer CM, Rogers LM, Bailey LB, Gregory JF, 3rd. Absorption of folate from fortified cereal-grain products and of supplemental folate consumed with or without food determined by using a dual-label stable-isotope protocol. *American Journal of Clinical Nutrition.* 1997;66(6):1388-1397.
112. Quinlivan EP, McPartlin J, McNulty H, et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. *Lancet.* 2002;359(9302):227-228.

113. Raats M, Thorpe L, Hurren C, Elliott K. Changing Preconceptions: The HEA Folic Acid Campaign, 1995-1998. *London, Health Education Authority.* 1998;2.
114. Ray JG, Meier C, Vermeulen MJ, Boss S, Wyatt PR, Cole DE. Association of neural tube defects and folic acid food fortification in Canada. *Lancet.* 2002;360(9350):2047-2048.
115. Ray JG, Meier C, Vermeulen MJ, Cole DE, Wyatt PR. Prevalence of trisomy 21 following folic acid food fortification. *American Journal of Medical Genetics. 120A.* 2003;3:309-313.
116. Ray JG, Vermeulen MJ, Boss SC, Cole DE. Increased red cell folate concentrations in women of reproductive age after Canadian folic acid food fortification. *Epidemiology.* 2002;13(2):238-240.
117. Ray JG, Vermeulen MJ, Langman LJ, Boss SC, Cole DE. Persistence of vitamin B12 insufficiency among elderly women after folic acid food fortification. *Clinical Biochemistry.* 2003;36(5):387-391.
118. Riddell LJ, Chisholm A, Williams S, Mann JI. Dietary strategies for lowering homocysteine concentrations. *American Journal of Clinical Nutrition.* 2000;71(6):1448-1454.
119. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. *JAMA.* 1998;279(5):359-364.
120. Rinsky-Eng J, Miller L. Knowledge, use, and education regarding folic acid supplementation: Continuation study of women in Colorado who had a pregnancy affected by a neural tube defect. *Teratology.* 2002;66(1).
121. Robinson K, Mayer E, Jacobsen DW. Homocysteine and coronary artery disease. *Cleveland Clinic Journal of Medicine.* 1994;61(6):438-450.
122. Rodrigues LC, Smith PG. Use of the case-control approach in vaccine evaluation: efficacy and adverse effects. *Epidemiologic Reviews.* 1999;21(1):56-72.
123. Rossi E, Beilby JP, McQuillan BM, Hung J. Biological variability and reference intervals for total plasma homocysteine. *Annals of Clinical Biochemistry.* 1999;36(Pt 1):56-61.
124. Rydlewicz A, Simpson JA, Taylor RJ, Bond CM, Golden MH. The effect of folic acid supplementation on plasma homocysteine in an elderly population. *QJM.* 2002;95(1):27-35.
125. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. *New England Journal of Medicine.* 2001;345(22):1593-1600.
126. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. *New England Journal of Medicine.* 1995;332(5):286-291.
127. Selhub J, Jacques PF, Rosenberg IH, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. *Annals of Internal Medicine.* 1999;131(5):331-339.
128. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. *JAMA.* 1993;270(22):2693-2698.

129. Seshadri G, Beiser A, Selhub J, al. e. Plasma homocysteine as a risk factor for dementia and alzheimer's disease. *New England Journal of Medicine.* 2002;345:1953-1960.
130. Skeaff M, Green T, Mann J. Mandatory fortification of flour? Science, not miracles, should inform the decision.[comment]. *New Zealand Medical Journal.* 2003;116(1168):U303.
131. Smithells RW, Nevin NC, Seller MJ, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. *Lancet.* 1983;1(8332):1027-1031.
132. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? [letter; comment.] [see comments.]. *New England Journal of Medicine.* 1995;332(5):328-329.
133. Stampfer MJ, Willett WC. Homocysteine and marginal vitamin deficiency. The importance of adequate vitamin intake. *JAMA.* 1993;270(22):2726-2727.
134. Stevens L. JAMA Patient Page - Vitamins A to K. *JAMA.* Vol 287; 2002:3166.
135. Stevenson RE, Allen WP, Pai GS, et al. Decline in prevalence of neural tube defects in a high-risk region of the United States. *Pediatrics.* 2000;106(4):677-683.
136. Than LC, Watkins M, Daniel KL. Serum folate levels among women attending family planning clinics--Georgia, 2000. *Morbidity & Mortality Weekly Report. Recommendations & Reports.* 2002;51(RR-13):4-8.
137. Tice JA, Ross E, Coxson PG, et al. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. *JAMA.* 2001;286(8):936-943.
138. Tucker KL, Mahnken B, Wilson PW, Jacques P, Selhub J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. *JAMA.* 1996;276(23):1879-1885.
139. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. *American Journal of Clinical Nutrition.* 1993;57(1):47-53.
140. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. *Journal of Nutrition.* 1994;124(10):1927-1933.
141. Ulrich CM, Kampman E, Bigler J, et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? *Cancer Epidemiology, Biomarkers & Prevention.* 1999;8(8):659-668.
142. van Oort FV, Melse-Boonstra A, Brouwer IA, et al. Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study. *American Journal of Clinical Nutrition.* 2003;77(5):1318-1323.
143. Vilter CF, Vilter RW, Spies TD. The treatment of pernicious and related anemias with synthetic folic acid: observations on maintenance of normal hematologic status and on occurrence of combined system disease at the end of one year. *J Lab and Clin Med.* 1947;32:262-273.
144. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *Bmj.* 2002;325(7374).

145. Wald NJ, Bower C. Folic acid and the prevention of neural tube defects. *BMJ.* 1995;310(6986):1019-1020.
146. Wald NJ, Hackshaw AK. Folic acid and miscarriage: an unjustified link. *American Journal of Medical Genetics.* 2001;98(2):204.
147. Wald NJ, Law MR, Morris JK, Wald DS. Quantifying the effect of folic acid. *Lancet.* 2001;358(9298):2069-2073.
148. Ward M, McNulty H, McPartlin J, Strain JJ, Weir DG, Scott JM. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. *QJM.* 1997;90(8):519-524.
149. Weber MB, Oakley GP. Fortifying foods with folic acid: an excellent opportunity to improve health. *AgroFood industry hi-tech.* May/June 2003 2003;14(3):42-44.
150. Wharton B, Booth I. Fortification of flour with folic acid. *BMJ.* 2001;323(7323):1198-1199.
151. Willett WC, Stampfer MJ. What vitamins should I be taking? *New England Journal of Medicine.* 2002;346(June 13, 2002):1915.
152. Williams LJ, Mai CT, Edmonds LD. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. *Teratology.* 2002;68:33-39.
153. Williams LJ, Mai CT, Edmonds LD, et al. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. *Teratology.* 2002;66(1):33-39.
154. Windham GC, Shaw G, Todoraff K, Swan S. Miscarriage and use of multivitamins or folic acid (letter). *American Journal of Medical Genetics.* 2000;90(3):261-262.
155. Woldesenbet S, Green T, Newton GR. H-type 1 carbohydrate antigen expression by ovine endometrial cells. *In Vitro Cellular & Developmental Biology. Animal.* 2002;38(6):358-364.
156. Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. *JAMA.* 1999;281(17):1632-1637.